A STAT3 DEGRADER DEMONSTRATES PRE-CLINICAL EFFICACY IN VENETOCLAX RESISTANT MDS & AML
Introduction: High-risk MDS & AML are the result of malignant transformation of an immature hematopoietic precursor. Venetoclax (Ven) is a selective inhibitor of the anti-apoptotic BCL2 protein that is FDA approved for the treatment of AML, despite which, the overall cure rates in HR-MDS and AML...
Sparad:
| Huvudupphov: | , , , , , , |
|---|---|
| Materialtyp: | Artigo |
| Språk: | Inglês |
| Utgiven: |
Elsevier
2024-01-01
|
| Serie: | Leukemia Research Reports |
| Länkar: | http://www.sciencedirect.com/science/article/pii/S2213048924000359 |
| Taggar: |
Inga taggar, Lägg till första taggen!
|